Nabriva Therapeutics AG (NBRV) Shares Down 1.7%

Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) were down 1.7% during mid-day trading on Thursday . The company traded as low as $8.20 and last traded at $8.40. Approximately 777,928 shares traded hands during trading, an increase of 81% from the average daily volume of 429,780 shares. The stock had previously closed at $8.26.

A number of analysts recently issued reports on NBRV shares. Cantor Fitzgerald reissued a “buy” rating and set a $16.00 target price on shares of Nabriva Therapeutics AG in a research report on Friday, September 1st. SunTrust Banks, Inc. started coverage on shares of Nabriva Therapeutics AG in a research report on Friday, August 25th. They set a “buy” rating and a $20.00 target price for the company. ValuEngine raised shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Zacks Investment Research raised shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating and set a $12.00 target price for the company in a research report on Tuesday, July 18th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 target price (up previously from $16.00) on shares of Nabriva Therapeutics AG in a research report on Monday, August 28th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. Nabriva Therapeutics AG has a consensus rating of “Buy” and an average price target of $19.13.

The stock’s market capitalization is $224.10 million. The stock’s 50 day moving average is $9.01 and its 200 day moving average is $10.19.

Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($5.83) by $5.29. The firm had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.34 million. On average, analysts forecast that Nabriva Therapeutics AG will post ($2.29) EPS for the current fiscal year.

In related news, major shareholder Hbm Healthcare Investments (Ca sold 13,127 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $10.94, for a total value of $143,609.38. Following the completion of the sale, the insider now directly owns 2,583,229 shares in the company, valued at approximately $28,260,525.26. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Vivo Capital Viii, Llc bought 52,631 shares of Nabriva Therapeutics AG stock in a transaction that occurred on Monday, September 18th. The stock was bought at an average price of $9.46 per share, with a total value of $497,889.26. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 279,000 shares of company stock valued at $2,870,869. Corporate insiders own 2.75% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of NBRV. Almanack Investment Partners LLC. lifted its holdings in Nabriva Therapeutics AG by 482.2% in the 2nd quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock worth $1,633,000 after purchasing an additional 751,366 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Nabriva Therapeutics AG by 9.9% in the 1st quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after purchasing an additional 193,951 shares during the last quarter. Nationwide Fund Advisors acquired a new stake in Nabriva Therapeutics AG in the 1st quarter worth approximately $2,074,000. Finally, Royal Bank of Canada lifted its holdings in Nabriva Therapeutics AG by 19.6% in the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 8,650 shares during the last quarter. Hedge funds and other institutional investors own 68.56% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Nabriva Therapeutics AG (NBRV) Shares Down 1.7%” was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.themarketsdaily.com/2017/09/21/nabriva-therapeutics-ag-nbrv-shares-down-1-7.html.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply